Stocks · News reference
Phathom Pharmaceuticals reported that the FDA has opened a public docket to solicit comments on regulatory issues related to an ANDA for VOQUEZNA, while the company has also intervened in ongoing litigation.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Phathom Pharmaceuticals announced its financial results for the third quarter of 2026, reporting $84.7 million in net revenue and a net loss of $13.9 million.
Filed: 2026-10-29 AccNo: 0001193125-26-436959 Size: 254 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits